文献速递神经肿瘤

弥漫性星形细胞胶质瘤,IDH1/2野生型,具有胶质母细胞瘤分子特征,WHO IV级:cIMPACT-NOW标准的验证

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
PubMed 文献 · Neuro Oncol · 2020-01-01

这项回顾性多中心研究比较了71例具有低级别胶质瘤影像学特征的IDH1/2野生型星形细胞瘤WHO IV级患者与197例IDH1/2野生型胶质母细胞瘤患者的总生存期,并比较了22例仅pTERT突变星形细胞瘤患者与胶质母细胞瘤患者的总生存期。结果显示两组总生存期相似,证实了cIMPACT-NOW推荐,作者提议将无其他合格突变的IDH1/2野生型星形细胞瘤WHO IV级归类为IDH1/2野生型胶质母细胞瘤。

要点

  • IDH1/2wt星形细胞瘤WHO IV级中位OS 23.8个月,IDH1/2wt胶质母细胞瘤19.2个月,HR 1.27(95%CI 0.85-1.88,P=0.242)。
  • 仅pTERTmt星形细胞瘤与IDH1/2wt胶质母细胞瘤OS相似,HR 1.15(95%CI 0.64-2.10,P=0.641)。
  • 数据证实cIMPACT-NOW推荐,作者提议将无其他合格突变的IDH1/2wt星形细胞瘤WHO IV级归类为IDH1/2wt胶质母细胞瘤。

核心结论

  • 数据证实了cIMPACT-NOW推荐,作者提议将无其他合格突变的IDH1/2wt星形细胞瘤WHO IV级归类为IDH1/2wt胶质母细胞瘤。

研究设计与样本

  • 回顾性多中心研究,比较71例具有低级别胶质瘤影像学特征的IDH1/2wt星形细胞瘤WHO IV级患者与197例IDH1/2wt胶质母细胞瘤患者的总生存期。
  • 另比较22例仅pTERTmt星形细胞瘤患者与IDH1/2wt胶质母细胞瘤患者的总生存期。

主要发现

  • IDH1/2wt星形细胞瘤WHO IV级患者中位OS为23.8个月,IDH1/2wt胶质母细胞瘤患者为19.2个月(Cox比例风险模型:HR 1.27,95%CI 0.85-1.88,P=0.242)。
  • 仅pTERTmt星形细胞瘤患者与IDH1/2wt胶质母细胞瘤患者OS相似(HR 1.15,95%CI 0.64-2.10,P=0.641)。

关键数值与推荐

  • cIMPACT-NOW推荐:IDH1/2wt弥漫性低级别胶质瘤WHO II或III级,若存在(i)pTERTmt和/或(ii)7号染色体获得合并10号染色体缺失和/或(iii)EGFR扩增,应重新分类为IDH1/2wt星形细胞瘤WHO IV级。

临床怎么用

  • 作者提议将无其他合格突变的IDH1/2wt星形细胞瘤WHO IV级归类为IDH1/2wt胶质母细胞瘤。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) World Health Organization (WHO) grade II or III that present with (i) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or (ii) gain of chromosome 7 combined with loss of chromosome 10, and/or (iii) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). This paper describes the overall survival (OS) of IDH1/2wt astrocytoma WHO IV patients, and more in detail patients with tumors with pTERTmt only. METHODS: In this retrospective multicenter study, we compared the OS of 71 IDH1/2wt astrocytomas WHO IV patients, with radiological characteristics of LGGs, with the OS of 197 IDH1/2wt glioblastoma patients. Moreover, we compared the OS of 22 pTERTmt only astrocytoma patients with the OS of the IDH1/2wt glioblastoma patients. RESULTS: Median OS was similar for IDH1/2wt astrocytoma WHO IV patients (23.8 mo) and IDH1/2wt glioblastoma patients (19.2 mo) (Cox proportional hazards model: hazard ratio [HR] 1.27, 95% CI: 0.85-1.88, P = 0.242). OS was also similar in patients with IDH1/2wt astrocytomas WHO IV, pTERTmt only, and IDH1/2wt glioblastomas (HR 1.15, 95% CI: 0.64-2.10, P = 0.641). CONCLUSIONS: The presented data confirm the cIMPACT-NOW recommendation and we propose that IDH1/2wt astrocytomas WHO IV in the absence of other qualifying mutations should be classified as IDH1/2wt glioblastomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020. PMID: 31637414. doi:10.1093/neuonc/noz200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。